Dallas, Texas (PRWEB) September 08, 2013
The global multiple sclerosis therapeutics market has the potential to grow to a value of $17.9 billion by 2019. The market is currently led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake.
Scope of the report Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth (http://www.rnrmarketresearch.com/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-market-report.html) covers:
A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.
In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.
Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.
Discussion of the drivers and barriers for market growth or decay.
Deals and Strategic Consolidations covered in the report available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=113287 includes:
Major Co-development Deals
1 Daiichi Sankyo Enters into an Agreement with Amplimmune
2 Karo Bio Enters into an Agreement with Pfizer
3 Proteostasis Enters into an Agreement with Elan
4 Lycera Enters into an Agreement with Merck
5 Facet Enters into an Agreement with Trubion
6 UCB Enters into an Agreement with Biogen
Major Licensing Deals
1 Addex Extends its Licensing Agreement with Merck
2 Biogen Enters into a Licensing Agreement with Acorda Therapeutics
3 Genzyme Enters into a Licensing Agreement with Bayer Healthcare
4 Novartis Enters into a Licensing Agreement with Peptimmune
5 Merck Serono Enters into a Licensing Agreement with Apitope Technology
6 Antisense Enters into a Licensing Agreement with Teva Pharmaceutical
7 BioMS Medical Corp Enters into a Licensing Agreement with Eli Lilly
8 Biotica Enters into an Agreement with Wyeth
Complete report Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth is available at http://www.rnrmarketresearch.com/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-market-report.html .
Explore more reports on Multiple Sclerosis at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/multiple-sclerosis-drugs .
RnRMarketResearch.com is an online market research reports (http://www.rnrmarketresearch.com/latest_reports) library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.